Paradromics and University of Michigan Complete First Connexus® BCI Implantation for the FDA-Approved Connect-One Clinical Study
· Financial Post
AUSTIN, Texas -- Paradromics Inc., a neurotechnology company that has developed the highest data-rate brain-computer interface (BCI) platform, announced today the completion of the first surgical implantation in the FDA-approved Connect-One Early Feasibility Study (EFS) at University of Michigan Health. The procedure was performed by Matthew Willsey, M.D., Ph.D., a neurosurgeon and biomedical engineer, with Aditya S. Pandey, M.D., and a multidisciplinary team of providers. Read More
Visit asg-reflektory.pl for more information.